Navigation Links
Former Bristol-Myers Squibb Senior Vice President Indicted for Lying to the Federal Government About Popular Blood-Thinning Drug
Date:4/23/2008

WASHINGTON, April 23 /PRNewswire-USNewswire/ -- The Department of Justice announced today that the former senior vice president of Bristol-Myers Squibb Company (BMS), Andrew Bodnar, was indicted for his role in lying to the federal government about a patent deal involving the popular blood-thinning drug, Plavix, used by heart attack, stroke and other patients. The Department said that the alleged illegal actions of Bodnar related to the possible introduction of a generic drug that would compete with Plavix.

On June 11, 2007, BMS agreed to plead guilty and pay a $1 million criminal fine for misleading the government about the Plavix patent deal. BMS paid the maximum fine permitted by statute for committing two violations under the federal False Statements Act.

According to the one-count indictment filed today in the U.S. District Court in Washington, D.C., in 2006, BMS and another company, Apotex Inc., were engaged in litigation over the validity of the patent for Plavix and were negotiating a settlement of that litigation. At the time, BMS was subject to a separate consent decree, for unrelated conduct, with the Federal Trade Commission (FTC) that required BMS to submit any proposed patent settlements for review and advisory approval by the FTC. The FTC warned BMS that if BMS agreed with Apotex not to launch BMS's own generic version of Plavix -- meaning that BMS would not compete against Apotex for generic sales -- then the FTC would not approve a settlement of the Plavix litigation.

In the indictment, the Department alleges that, at a meeting in 2006, Bodnar, on behalf of BMS, made representations to Apotex to reassure it that BMS would not launch a generic version of Plavix if Apotex agreed to a settlement which would prevent Apotex from launching its Plavix generic until 2011. The Department charges that Bodnar knowingly and willfully made a false statement to the FTC about the existence of his representations to Apotex.

"Lying to the federal government is a serious felony that obstructs the law enforcement process," said Thomas O. Barnett, Assistant Attorney General in charge of the Department's Antitrust Division. "The Department of Justice will vigorously prosecute such illegal activity."

Plavix, a patented pharmaceutical, is the most widely prescribed blood-thinning drug in the world. Approximately 48 million Americans take Plavix daily to prevent potentially fatal blood clots. The drug was approved for sale in the U.S. in November 1997.

BMS, an international pharmaceutical company headquartered in New York, N.Y, participates in the sale and marketing of Plavix in the U.S. through the Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, which sold more than $3.5 billion of Plavix in the U.S. in 2005.

Bodnar is charged with a violation of the Federal False Statements Act, which carries a maximum sentence of five years of imprisonment and a fine of $250,000. The fine may be increased to twice the gain from the offense or twice the loss incurred by the victims of the crime.

This case is part of an ongoing investigation being conducted by the Antitrust Division's National Criminal Enforcement Section and the New York Field Office of the Federal Bureau of Investigation. Anyone with information about this matter should contact the Antitrust Division's National Criminal Enforcement Section at 202-307-6694.


'/>"/>
SOURCE U.S. Department of Justice
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. 4-Star Gen. Barry Mccaffrey, Former U.S. Drug Czar, to Keynote Recovery Happens! Rally for Treatment: Wed., Sept. 5, 11 Am, State Capitol West Steps, Sacramento
2. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Former State Representative Terry Parke Joins Secure Services Corp.
5. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
6. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, & Countrys Top Drug Treatment CEO Barry Karlin to Keynote Palm Beach, FL National Moment Of Change Intervention Conference:
7. Former Ronco President Tim Dupler Signs International Direct Sales and Marketing Contract with Natural Nutrition
8. Former HHS Secretary Dr. Louis Sullivan, Lt. Gov. Cagle Address Need to Improve Quality of Patient Care
9. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
10. Nobel Honors 3 Former March of Dimes Prize Recipients
11. Over one-third of former American football players had sexual relations with men, study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: